Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers. The patent, licensed from The University of British Columbia, includes coverage for the method for treating cancers that express the protein clusterin using OGX-011, or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex. "Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011."

OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67 granted or issued U.S. and foreign patents, and approximately 140 pending U.S. and foreign patent applications worldwide. Composition of matter patents covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the U.S. and certain other jurisdictions. Additional patent applications covering all of these products, as well as other technologies, are pending in the U.S. and certain other countries. TRPM-2 is an historical name for clusterin, and survives in some of the earlier patent filings.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and c
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell Lindgren ... month on his first mission to the International Space ... 8 to 9 a.m. EDT Tuesday, July 7. ... Star City, Russia . The interviews will ... Television highlighting his mission training. To schedule an ...
(Date:6/30/2015)... WA (PRWEB) , ... June 30, 2015 , ... ... a hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates ... combines extremely fine pores with significant open space to allow easy liquid flow ...
(Date:6/30/2015)... , June 30, 2015  The University of ... Biosciences (CCE/Bio) and UC San Diego Extension announced ... be held Aug.  12 – 14, 2015, at ... three-day workshop provides an intense exposure to best ... and is well-suited to biologists, process engineers and ...
(Date:6/30/2015)... IL (PRWEB) , ... June 30, 2015 , ... ... effective August 14. She has accepted the position of vice president of instruction ... August 17. , “I greatly appreciated the opportunity to lead SIUE during ...
Breaking Biology Technology:NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... diagnostics for animals and humans, today,announced that it ... a private placement with a group of existing ... AspenBio will receive,approximately $18 million in gross proceeds ...
... N.J., Dec. 20 Memory,Pharmaceuticals Corp. (Nasdaq: ... in a randomized, double-blind, placebo-controlled Phase 2a clinical,trial ... receptor partial,agonist, in cognitive impairment associated with schizophrenia ... tolerability and cognitive effects,of three doses of MEM ...
... /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: CHBT), a ... marketing and,distribution of probiotics dietary supplements, today announced ... Eastern Time on Monday, August 13,2007, to discuss ... June 30, of its 2008 fiscal year. ...
Cached Biology Technology:AspenBio Pharma Announces $18 Million Private Placement of Common Stock 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results 2
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... in the brains of rats to help focus ... sensory pathways to make it easier to block ... found. , Their report in the Journal of ... with attention deficit and hyperactivity disorders to improve ...
... unique nanoparticles that convert laser light into useful information, ... pH meter. , The discovery, which appears online this ... the first potential means of measuring accurate pH changes ... tissue and cells. , "Almost every biologist I speak ...
... PLoS Genetics has published the findings of a team ... Institute that provides a whole genome analysis of the ... as Dictyostelium. , Led by Dr. Janet ... of kinases, which are enzymes involved in cell communication ...
Cached Biology News:Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3Rice scientists make first nanoscale pH meter 2Scientists elucidate the kinome of key model organism 2
...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
... Perfuse cells right in your ... The Petri dish Perfusion Chamber has ... outflow that dampen the fluctuations of ... compartment and prevent bubbles from entering ...
... Promega Flipper® Racks are ideal for storage ... tubes. These polypropylene racks withstand extreme temperatures, ... storage. They may also be autoclaved for ... two-sided; one side accommodates 0.5ml microcentrifuge tubes, ...
Biology Products: